Navigation Links
BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
Date:8/9/2012

LYNBROOK, N.Y., Aug. 9, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced its financial results for the second quarter ended June 30, 2012 and provided a corporate update.

"We are very pleased with the clinical and regulatory progress of XIAFLEX in recent months and are excited about the upcoming anticipated milestones for the remainder of this year," reflected Thomas L. Wegman, President of BioSpecifics. "We announced positive top-line results from Auxilium's two IMPRESS Phase III clinical trials of XIAFLEX for Peyronie's disease in June and expect Auxilium to submit a sBLA filing by the end of the year. BioSpecifics also initiated two Phase II clinical trials in canine and human lipomas and we anticipate we will complete enrollment for both of these studies in the first half of 2013. Additionally, XIAFLEX was recently approved in Canada for Dupuytren's contracture and Auxilium's partner Actelion expects to file for approval in Australia, Brazil and Mexico by the end of 2012."

Second Quarter 2012 Financial ResultsBioSpecifics reported a net income of $0.7 million for the second quarter ended June 30, 2012, or $0.11 per basic and $0.10 per diluted share, compared to a net income of $2.6 million, or $0.40 per basic and $0.36 per diluted share, for the same period in 2011.

Total revenue for the second quarter of 2012 was $2.6 million, compared to $5.0 million for the same period in 2011.

Royalty, mark-up on cost of goods sold, and earn-out revenues for the second quarter ended June 30, 2012 were $2.5 million, compared to $1.7 million for the same period in 2011. Royalty and mark-up on cost of goods sold revenues recognized under the Comp
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
2. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
3. Frost & Sullivan Recognizes MicroProtein Technologies for its Path-Breaking Production Technology for Recombinant Proteins in Bacteria
4. Life Technologies Announces $750 Million Share Repurchase Program
5. The PROOF Centre of Excellence Partners with OriGene Technologies on Heart & Kidney Transplant Biomarker Program
6. Life Technologies Moving "Off the Grid" with Clean Energy Fuel Cells
7. BioStorage Technologies Continues Global Growth; Announces Strategic Expansion Into Asia Pacific and New General Manager APAC
8. Life Technologies Sets 2nd Quarter 2012 Earnings Release Date for Tuesday, July 31, 2012
9. Life Technologies to Accelerate Development of Ion Torrent Semiconductor Technology for Proteomic Applications in Research, Applied and Clinical Markets
10. Ethical Corporation Names Life Technologies First CSO Sustainability Executive of the Year
11. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... PharmaVentures announced today that it was delighted ... deal which won Scrip,s ,Outsourcing Deal of the Year 2011,. ... it was "one the largest and most comprehensive R&D alliances ... terms of the agreement, Sanofi retains access to some of ...
... BETHESDA, Md., Jan. 11, 2012   Spherix Incorporated (NASDAQ: ... therapy in diabetes, metabolic syndrome and atherosclerosis, and ... food, supplement, biotechnology and pharmaceutical companies, today reported ... study of its drug candidate, SPX-106.  Results demonstrated ...
... Calif., Jan. 11, 2012 IndustryWeek magazine today ... LIFE ) plant in Austin, Texas, one of its Top ... first biotechnology facility to win the prestigious award.  IndustryWeek ... improvement in gross margins since 2007; 94% error reduction in ...
Cached Biology Technology:PharmaVentures' Client Sanofi Wins Scrip 'Outsourcing Deal of the Year Award' 2Spherix Announces Successful Completion of Important Toxicology Study of SPX-106 2Spherix Announces Successful Completion of Important Toxicology Study of SPX-106 3Life Technologies Plant in Austin, Texas Named One of IndustryWeek's Top Ten Best Plants for 2011 2Life Technologies Plant in Austin, Texas Named One of IndustryWeek's Top Ten Best Plants for 2011 3Life Technologies Plant in Austin, Texas Named One of IndustryWeek's Top Ten Best Plants for 2011 4
(Date:4/17/2014)... study suggests that fish consumption advisories for expecting ... long-lived contaminants like persistent organic pollutants (POPs). ... researchers including University of Toronto Scarborough PhD student ... how different levels of environmental contamination, a mother,s ... in the body influenced exposure in her children. ...
(Date:4/17/2014)... Kansas State University engineer has developed a patented ... improvised explosive devices. The same technique could help ... Steven M. and Kay L. Theede chair in ... engineering, and his research team have created a ... in car trunks. The distance detection method ...
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... have identified a relationship between two proteins in the brain ... finding has led to speculation that existing drugs used to ... therapies to alleviate the symptoms of autism. The discovery ... neurexin-1 gene, which is located in brain cells and assists ...
... team of researchers led by North Carolina State University has ... Puerto Rico,s most remarkable ecosystems by conducting the first comprehensive ... Thomas Kwak, who led the study, says many of these ... calls the research "a huge first step in conserving and ...
... human civilisation was the practice of sustainable agriculture. But we ... for over 50 million years. Just as farming helped humans ... become dominant herbivores, and one of the most successful social ... issue of Microbiology Today, leaf-cutter ants have developed a system ...
Cached Biology News:Researchers find link between nicotine addiction and autism 2Researchers find link between nicotine addiction and autism 3NC State takes research lead in protecting Puerto Rico's unique freshwater fisheries 2Farming and chemical warfare: A day in the life of an ant? 2Farming and chemical warfare: A day in the life of an ant? 3
WD-repeat protein 4...
... Cultured human omental ... obese but otherwise healthy ... availability of diabetic cells. ... information. Support media also ...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Biology Products: